Litigation Details for SUMITOMO DAINIPPON PHARMA CO., LTD. v. AUROBINDO PHARMA LTD. (D.N.J. 2018)

SUMITOMO DAINIPPON PHARMA CO., LTD. v. AUROBINDO PHARMA LTD. (D.N.J. 2018)

Docket	2:18-cv-02620	Date Filed	2018-02-23
Court	District Court, D. New Jersey	Date Terminated	2018-07-23
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	Defendant	Referred To	Cathy L. Waldor
Patents	8,729,085; 8,883,794; 9,259,423; 9,555,027; 9,827,242
Link to Docket	External link to docket

Details for SUMITOMO DAINIPPON PHARMA CO., LTD. v. AUROBINDO PHARMA LTD. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-02-23				External link to document

Litigation Summary and Patent-Strength Analysis: Sumitomo Dainippon Pharma Co., Ltd. v. Aurobindo Pharma Ltd., 2:18-cv-02620

Last updated: July 17, 2026

Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo Dainippon”) sued Aurobindo Pharma Ltd. (“Aurobindo”) in the U.S. District Court for the District of New Jersey under the Hatch-Waxman Act in case 2:18-cv-02620. The record below is organized for litigation and exclusivity risk review: asserted patent estate, Paragraph IV posture, typical remedies sought, timeline of key filings, and infringement and validity attack surfaces.

---

What patents were asserted in Sumitomo Dainippon v. Aurobindo Pharma, 2:18-cv-02620?

Immediate answer (case-level): The litigation involved Hatch-Waxman patent assertions tied to an Aurobindo generic/ANDA entry, with Sumitomo Dainippon asserting one or more Orange-Book-listed patents covering the branded product and seeking injunctive relief and damages.

How to read the patent estate in this case In Hatch-Waxman generics, asserted patents typically fall into these buckets:

• Drug substance and/or composition of matter
• Formulation patents (e.g., excipient system, film-coating, salts/polymorphs, controlled release)
• Method-of-use patents (therapeutic dosing regimens, patient subsets, endpoints)
• Manufacturing method patents (process parameters, crystallization conditions)
• Exclusivity-adjacent patents (patents that delay launch even if some other patents expire)

Patent coverage mapping framework (useful for claim charts)

• Identify asserted claims by independent claim type (composition vs method).
• Map alleged infringement to ANDA drug label sections:
  • proposed indications
  • dosage and administration
  • formulation/dosage form language
  • any “section viii” details tied to manufacture or equivalence claims.
• Track validity arguments:
  • 35 USC 102/103 anticipation and obviousness
  • 35 USC 112 indefiniteness/written description
  • 35 USC 101 (if asserted in the filing record)
  • inequitable conduct (if pled)
• Track enforceability and remedy:
  • injunction scope depends on claim types that remain valid and infringed
  • damages hinge on launch timing and “at-risk” sales.

---

What was the litigation posture in 2:18-cv-02620: infringement, validity, and Hatch-Waxman Paragraph IV?

Immediate answer (posture): The case followed the standard Paragraph IV framework: Sumitomo Dainippon alleged Aurobindo’s ANDA certification(s) of non-infringement and/or invalidity were wrongful for the asserted Orange-Book patents, and Sumitomo Dainippon sought statutory remedies.

Common claim-level infringement logic in these cases

• Composition/formulation: infringement typically turns on whether the ANDA product is within the claimed formulation parameters.
• Method-of-use: infringement turns on whether the ANDA label induces or suggests the patented method.
• Manufacturing/process: infringement turns on whether the process practiced by the generic maps to the claimed process steps/parameters.

Common validity attack surfaces

• Prior art searches align with generic ANDA equivalency data:
  • known formulations
  • known dosage regimens
  • known manufacturing steps
• Written description and enablement disputes:
  • whether the specification supports the claimed range and specific embodiments
• Indefiniteness:
  • claim boundaries for functional limitations or ranges
• Obviousness combinations:
  • mix-and-match arguments between known actives, known excipients, and known release profiles.

---

When did the case begin, and what does the procedural timeline indicate about launch risk?

Immediate answer: Case number 2:18-cv-02620 indicates a filing in 2018. Procedural timelines in Hatch-Waxman suits usually determine:

• the likelihood of temporary stay
• the window in which Aurobindo could face an injunction
• whether the case proceeds to trial or resolves through settlement.

Litigation-stage indicators for risk For launch planning, the critical milestones in these actions are:

• complaint filing and service
• answer and counterclaims
• claim construction schedule
• summary judgment motions
• trial date set and dispositive motion outcomes
• any final judgment and appeal.

Why this matters

• If validity survives claim construction, injunction risk increases.
• If patents are narrowed or found invalid, Aurobindo’s “at-risk” launch risk typically decreases.

---

How do Paragraph IV certifications affect exclusivity and FDA marketing timing in this dispute?

Immediate answer: Under Hatch-Waxman, an ANDA with a Paragraph IV certification triggers a statutory litigation mechanism that can delay marketing while the infringement case is pending, depending on:

• whether the suit is brought within statutory timelines
• whether a court issues an infringement injunction
• whether the asserted patents are found invalid or not infringed.

Exclusivity timeline logic The practical timing effect is:

• Filing of Paragraph IV litigation can create an automatic stay of approval/launch while the case is pending (subject to statutory mechanics).
• Final outcome determines whether the generic can market and whether damages are owed for pre-judgment “at risk” sales after any court-permitted launch.

---

What remedy did Sumitomo Dainippon seek against Aurobindo, and how does it shape settlement leverage?

Immediate answer: Sumitomo Dainippon’s requested remedies in a Hatch-Waxman action typically include:

• injunctive relief to block FDA approval/marketing as to the asserted patents
• damages (and potentially enhanced damages) under 35 USC 271(e)(4) for infringing acts tied to the ANDA filing.

Settlement leverage mechanics

• If key patents appear strong on claim construction, the branded side can extract:
  • design-around commitments
  • launch-date settlements
  • ongoing royalties or licensing fees
• If key patents appear vulnerable (prior art, written description), the generic side can push for:
  • stipulations of non-infringement
  • early resolution with limited or no monetary component.

---

What is the typical court path in these Hatch-Waxman cases, and what does it imply for 2:18-cv-02620?

Immediate answer: Hatch-Waxman patent cases in federal court commonly track:

1. pleadings and counterclaims
2. claim construction
3. summary judgment (sometimes on non-infringement/invalidity)
4. trial (or settlement)
5. final judgment and appeal.

Risk translation for investors and licensing teams

• Settlement before claim construction often correlates with perceived strength gaps or business pressure.
• Settlement after claim construction often correlates with refined infringement/validity risk and a narrower set of remaining asserted claims.

---

How strong is the patent estate for Sumitomo Dainippon in litigation like this: what claims usually survive?

Immediate answer: In generic challenges, survival rates typically hinge on whether:

• composition claims are supported by clear structural/formulation limitations
• method claims are clearly tied to label language and have defensible novelty
• process claims are supported with concrete steps and ranges.

Analytical lenses

• Claim scope clarity: whether “means-plus-function” or functional limits invite indefiniteness.
• Prior art closeness: whether the prior art teaches the claimed ranges and essential limitations.
• Enablement: whether the patent specification supports breadth without undue experimentation.
• Secondary considerations: when available, these can buttress obviousness.

---

What generic entry risks existed for Aurobindo if patents were invalidated or narrowed?

Immediate answer: If the asserted patents were found invalid or not infringed, Aurobindo could potentially:

• receive or keep FDA approval
• launch at risk if non-infringement or invalidity is not stayed by appellate process
• face narrower remaining patent constraints only if other Orange-Book patents exist and were not asserted or stayed.

Launch-risk checklist

• Identify any unasserted Orange-Book patents still potentially enforceable.
• Confirm whether remaining patents attach to:
  • the same dosage form
  • the same route (oral vs other)
  • the same dosage strength
  • the same patient population or dosing regimen.

---

Which firms and judges typically appear in District of New Jersey Hatch-Waxman disputes, and how does that impact case strategy?

Immediate answer: District of New Jersey Hatch-Waxman cases usually involve:

• specialized pharma IP counsel on both sides
• claim construction handled through Markman scheduling
• strong use of PTAB or prior art mapping to attack novelty.

Case strategy implications

• Early claim construction can force both sides into either:
  • a narrowing settlement or
  • a “win-or-lose” trial posture on the remaining essential claims.

---

How does this dispute compare with other Sumitomo Dainippon vs generic challengers in Hatch-Waxman litigation?

Immediate answer: Sumitomo Dainippon’s litigation posture in generic challenges typically follows the established pattern:

• broad asserted patent estate
• emphasis on one or more core patents (composition/formulation) while pruning weaker dependent claims.

Comparability dimensions

• whether the branded product has:
  • complex formulation IP
  • multiple method-of-use patents
  • strong manufacturing know-how encoded in process claims
• whether the generic’s ANDA includes:
  • identical excipient system
  • identical dosage regimen language
  • matching release profile or polymorph characteristics.

---

Orange Book status and FDA pathway: what does the ANDA posture suggest about marketing timing?

Immediate answer: The case implies an ANDA with Paragraph IV certifications against Orange-Book-listed patents. Under Hatch-Waxman, Orange Book listing determines:

• whether the ANDA must certify against each listed patent
• whether statutory stay triggers follow.

Regulatory timing impact

• If Aurobindo’s approval remains stayed pending litigation, launch timing is court-driven.
• If litigation ends in favor of Aurobindo, marketing proceeds under FDA approval status.

---

Key Takeaways

• 2:18-cv-02620 is a Hatch-Waxman patent litigation brought by Sumitomo Dainippon against Aurobindo over an ANDA-linked Paragraph IV challenge.
• The business outcome turns on the core asserted patent claim types (composition/formulation vs method-of-use) and the court’s claim construction.
• For launch and licensing planning, the case is a timing lever: Paragraph IV litigation can delay marketing, while final invalidity/non-infringement findings can open launch absent additional unasserted Orange-Book barriers.
• Litigation leverage typically pivots at claim construction and summary judgment, which controls whether settlement occurs early or after narrowing.

---

FAQs

1. What is the practical difference between composition/formulation and method-of-use patent risk in Hatch-Waxman cases?
2. How do court claim constructions usually change settlement value in Paragraph IV disputes?
3. What “unasserted” Orange Book patents can still block launch even after a win on some asserted claims?
4. When do appeal timelines materially change at-risk launch decisions for generic applicants?
5. How do excipient and release-profile details in ANDAs typically drive formulation infringement analyses?

---

References (APA)

1. U.S. District Court for the District of New Jersey. Sumitomo Dainippon Pharma Co., Ltd. v. Aurobindo Pharma Ltd., No. 2:18-cv-02620. (Case filings and docket).